Phase II trial with S-1 in chemotherapy-naı̈ve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)

This publication has 12 references indexed in Scilit:

• Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid Tumors
  Journal of Clinical Oncology, 2000
• Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
  British Journal of Cancer, 2000
• Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
  Oncology, 2000
• An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers
  Oncology, 1999
• Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients
  European Journal Of Cancer, 1998
• Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
  Anti-Cancer Drugs, 1996
• Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer
  Cancer, 1982
• Ocular Side Effects with 5‐Fluorouracil
  Australian and New Zealand Journal of Medicine, 1979
• Factors related to survival following resection for gastric carcinoma.Analysis of 903 cases
  Cancer, 1977
• The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent
  Journal of Chronic Diseases, 1961